Impact of five‐tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high‐dose‐rate brachytherapy

Tsumura, Hideyasu; Ishiyama, Hiromichi; Tabata, Ken‐ichi; Katsumata, Hiroki; Kobayashi, Momoko; Ikeda, Masaomi; Kurosaka, Shinji; Fujita, Tetsuo; Kitano, Masashi; Satoh, Takefumi; Yanagisawa, Nobuyuki; Hayakawa, Kazushige

doi:10.1002/pros.23430

Cited by 7 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other poor prognosis factors, such as a high Gleason score (≥ 8), high tumor infiltration on prostate biopsy and extracapsular extension were also identified as poor prognostic factors in several surgical and BT series [8,10,14,49,59], as well as in our series in univariate analysis.…”

Section: Discussionsupporting

confidence: 63%

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

et al. 2019

View full text Add to dashboard Cite

ObjectivesNo study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer.Materials and methodsThis retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data.ResultsA total of 276 T3b patients were included. The median follow-up was 26 months. The median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70–80) and 76 (46–80), respectively. The dose constraint recommendations were exceeded in less than 12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5-year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and 15%, respectively. The number of involved lymph nodes (≤ 2 or ≥ 3) on MRI was the only significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade ≥ 2 acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and 31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were predictive of late digestive toxicity.ConclusionIMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of recurrence and death.

show abstract

Section: Discussionsupporting

confidence: 63%

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our data partly concurred with their data because a significant threshold to separate PCSM with the highest hazard ratio was obtained between T3a and T3b and Gleason score sum 8 and 9, but not in iPSA ( Table 3 ). Tsumura et al reported similar results that stage T3b patients with grade group 5 may have a greater risk for PCSM [ 20 ].…”

Section: Discussionmentioning

confidence: 88%

Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors

Yamazaki

Suzuki

Masui

et al. 2021

Cancers

View full text Add to dashboard Cite

This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.

show abstract

“…A total of eight studies were selected for inclusion in the meta-analysis, all of which were retrospective series classified as Level 4 evidence [14] , [20] , [21] , [22] , [23] , [24] , [25] , [26] . Four reported data from a single institution, while the remaining four were multi-institutional.…”

Section: Resultsmentioning

confidence: 99%

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis

Tang¹,

Gulstene²,

McArthur³

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Impact of five‐tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high‐dose‐rate brachytherapy

Cited by 7 publications

References 35 publications

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors

Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis

Contact Info

Product

Resources

About